Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy-Reference-Cited by-同舟云学术

Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy

Published:2020-01 Issue:1 Volume:19 Page:43-50
ISSN:1538-4721
Container-title:Brachytherapy
language:en
Short-container-title:Brachytherapy

Author:

Tom Martin C.,Reddy Chandana A.,Smile Timothy D.,Zhang Ryan X.,Ciezki Jay P.,Stephans Kevin L.,Mian Omar Y.,Klein Eric A.,Campbell Steven,Ulchaker James,Angermeier Kenneth,Tendulkar Rahul D.

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology

Reference15 articles.

1. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer;D'Amico;JAMA,1998

2. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy;Zumsteg;Eur Urol,2013

3. International multicenter validation of an intermediate risk subclassification of prostate cancer managed with radical treatment without hormone therapy;Berlin;J Urol,2019

4. Long-term Efficacy and toxicity of low-dose-rate (1)(2)(5)I prostate brachytherapy as monotherapy in low-, intermediate-, and high-risk prostate cancer;Kittel;Int J Radiat Oncol Biol Phys,2015

5. Risk group and death from prostate cancer: Implications for active surveillance in men with favorable intermediate-risk prostate cancer;Raldow;JAMA Oncol,2015

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate Cancer, Version 3.2024;Journal of the National Comprehensive Cancer Network;2024-04

2. LDR-Brachytherapy monotherapy appears unsuited for NCCN unfavorable intermediate-risk prostate cancer patients;Urologic Oncology: Seminars and Original Investigations;2023-11

3. Revisiting current National Comprehensive Cancer Network (NCCN) high-risk prostate cancer stratification: a National Cancer Database analysis;Prostate Cancer and Prostatic Diseases;2023-01-14

4. French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease;Progrès en Urologie;2022-11

5. Hypofractionated Radiotherapy in Intermediate-Risk Prostate Cancer Patients: Long-Term Results;Journal of Clinical Medicine;2022-08-16